$800 million IPO "just one option" for personalized oncology specialist

Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise  just shy of a billion dollars in a US listing.

“People familiar with the plan” told Reuters that two banks have already been hired to steer a listing on the Nasdaq exchange later this year, which would value the personalized medicine specialist at about $4 billion.

While press reports intimate that a listing is practically inevitable in the short term, chief operating officer Sean Marett is less certain the firm will go down this route.